For research use only. Not for therapeutic Use.
Delimotecan（Cat No.:I006428）is a synthetic camptothecin derivative with potent anticancer activity, functioning as a topoisomerase I inhibitor. Topoisomerase I is an enzyme involved in DNA replication and repair, and by inhibiting its activity, delimotecan interferes with DNA replication, leading to cancer cell death. It has been investigated for the treatment of various cancers, including solid tumors such as colorectal, lung, and ovarian cancers. Delimotecan is of particular interest due to its improved solubility and pharmacokinetic properties compared to other camptothecin derivatives. Ongoing clinical trials are evaluating its safety, efficacy, and potential for combination therapies in oncology.
| Catalog Number | I006428 |
| CAS Number | 187852-63-7 |
| Synonyms | Delimotecan; MEN-4901; MEN4901; MEN 4901; T-0128; T 0128; T0128;(S)-2-amino-N-(2-((2-((3-((4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3/’,4/’:6,7]indolizino[1,2-b]quinolin-9-yl)oxy)propyl)amino)-2-oxoethyl)amino)-2-oxoethyl)acet |
| Molecular Formula | C31H36N6O8 |
| Purity | ≥95% |
| Target | DNA Topoisomerase I Inhibitor |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4°C for short term or -20 °C for long term |
| IUPAC Name | 2-amino-N-[2-[[2-[3-[[(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl]oxy]propylamino]-2-oxoethyl]amino]-2-oxoethyl]acetamide |
| InChI | InChI=1S/C31H36N6O8/c1-3-18-19-10-17(44-9-5-8-33-26(39)13-35-27(40)14-34-25(38)12-32)6-7-23(19)36-28-20(18)15-37-24(28)11-22-21(29(37)41)16-45-30(42)31(22,43)4-2/h6-7,10-11,43H,3-5,8-9,12-16,32H2,1-2H3,(H,33,39)(H,34,38)(H,35,40)/t31-/m0/s1 |
| InChIKey | MWOPHYKKEDTKAZ-HKBQPEDESA-N |
| SMILES | CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OCCCNC(=O)CNC(=O)CNC(=O)CN |
| Reference | </br>1:Antitumor activity of delimotecan against human metastatic melanoma: pharmacokinetics and molecular determinants. Bigioni M, Parlani M, Bressan A, Bellarosa D, Rivoltini L, Animati F, Crea A, Bugianesi R, Maggi CA, Manzini S, Binaschi M.Int J Cancer. 2009 Nov 15;125(10):2456-64. doi: 10.1002/ijc.24661. PMID: 19536774 Free Article</br>2:Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors. Veltkamp SA, Witteveen EO, Capriati A, Crea A, Animati F, Voogel-Fuchs M, van den Heuvel IJ, Beijnen JH, Voest EE, Schellens JH.Clin Cancer Res. 2008 Nov 15;14(22):7535-44. doi: 10.1158/1078-0432.CCR-08-0438. PMID: 19010872 Free Article |
